The Impact of Prostate Cancer Treatment on Quality of Life: A Narrative Review with a Focus on Randomized Data

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.2159031912902
   PubMed Web of Science ®Google Scholar
• Albertsen PC. Observational studies and the natural history of screen-detected prostate cancer. Curr Opin Urol. 2015;25(3):232–237. doi:10.1097/MOU.000000000000015725692723
   PubMed Web of Science ®Google Scholar
• Bill-Axelson A, Holmberg L, Garmo H, et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med. 2014;370(10):932–942. doi:10.1056/NEJMoa131159324597866
   PubMed Web of Science ®Google Scholar
• Hamdy FC, Donovan JL, Lane JA, et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med. 2016;375(15):1415–1424. doi:10.1056/NEJMoa160622027626136
   PubMed Web of Science ®Google Scholar
• Wilt TJ, Jones KM, Barry MJ, et al. Follow-up of prostatectomy versus observation for early prostate cancer. N Engl J Med. 2017;377(2):132–142. doi:10.1056/NEJMoa161586928700844
   PubMed Web of Science ®Google Scholar
• Mohler JL, Antonarakis ES, Armstrong AJ, et al. Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17(5):479–505. doi:10.6004/jnccn.2019.002331085757
   PubMed Web of Science ®Google Scholar
• Wallis CJD, Glaser A, Hu JC, et al. Survival and complications following surgery and radiation for localized prostate cancer: an international collaborative review. Eur Urol. 2018;73(1):11–20. doi:10.1016/j.eururo.2017.05.05528610779
   PubMed Web of Science ®Google Scholar
• Dearnaley D, Syndikus I, Mossop H, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, Phase 3 CHHiP trial. Lancet Oncol. 2016;17(8):1047–1060. doi:10.1016/S1470-2045(16)30102-427339115
   PubMed Web of Science ®Google Scholar
• Catton CN, Lukka H, Gu C-S, et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. J Clin Oncol. 2017;35(17):1884–1890. doi:10.1200/JCO.2016.71.739728296582
   PubMed Web of Science ®Google Scholar
• Lee WR, Dignam JJ, Amin MB, et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol. 2016;34(20):2325–2332. doi:10.1200/JCO.2016.67.044827044935
   PubMed Web of Science ®Google Scholar
• Widmark A, Gunnlaugsson A, Beckman L, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet London Engl. 2019;394(10196):385–395. doi:10.1016/S0140-6736(19)31131-6
   PubMed Web of Science ®Google Scholar
• King CR, Freeman D, Kaplan I, et al. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective Phase II trials. Radiother Oncol. 2013;109(2):217–221. doi:10.1016/j.radonc.2013.08.03024060175
   PubMed Web of Science ®Google Scholar
• Zumsteg ZS, Spratt DE, Pei I, et al. A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy. Eur Urol. 2013;64(6):895–902. doi:10.1016/j.eururo.2013.03.03323541457
   PubMed Web of Science ®Google Scholar
• D’Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004;292(7):821–827. doi:10.1001/jama.292.7.82115315996
   PubMed Web of Science ®Google Scholar
• Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma: long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys. 2005;61(5):1285–1290. doi:10.1016/j.ijrobp.2004.08.04715817329
   PubMed Web of Science ®Google Scholar
• Roach M, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol. 2008;26(4):585–591. doi:10.1200/JCO.2007.13.988118172188
   PubMed Web of Science ®Google Scholar
• Bolla M, Van Tienhoven G, Warde P, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol. 2010;11(11):1066–1073. doi:10.1016/S1470-2045(10)70223-020933466
   PubMed Web of Science ®Google Scholar
• Bolla M, Maingon P, Carrie C, et al. Short androgen suppression and radiation dose escalation for intermediate- and high-risk localized prostate cancer: results of EORTC trial 22991. J Clin Oncol. 2016;34(15):1748–1756. doi:10.1200/JCO.2015.64.805526976418
   PubMed Web of Science ®Google Scholar
• Nabid A, Carrier N, Vigneault E, et al. A phase III trial of short-term androgen deprivation therapy in intermediate-risk prostate cancer treated with radiotherapy. J Clin Oncol. 2015;33(15_suppl):5019. doi:10.1200/jco.2015.33.15_suppl.5019
   Web of Science ®Google Scholar
• Morris WJ, Tyldesley S, Rodda S, et al. Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol. 2017;98(2):275–285. doi:10.1016/j.ijrobp.2016.11.026
   PubMed Web of Science ®Google Scholar
• Horwitz EM, Bae K, Hanks GE, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase iii trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol. 2008;26(15):2497–2504. doi:10.1200/JCO.2007.14.902118413638
   PubMed Web of Science ®Google Scholar
• Bolla M, de Reijke TM, Van Tienhoven G, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med. 2009;12:2516–2527.
   Web of Science ®Google Scholar
• Pisansky TM, Hunt D, Gomella LG, et al. Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910. J Clin Oncol. 2015;33(4):332–339. doi:10.1200/JCO.2014.58.066225534388
   PubMed Web of Science ®Google Scholar
• Denham JW, Steigler A, Lamb DS, et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol. 2011;12(5):451–459. doi:10.1016/S1470-2045(11)70063-821440505
   PubMed Web of Science ®Google Scholar
• Zapatero A, Guerrero A, Maldonado X, et al. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial. Lancet Oncol. 2015;16(3):320–327. doi:10.1016/S1470-2045(15)70045-825702876
   PubMed Web of Science ®Google Scholar
• Fizazi K, Faivre L, Lesaunier F, et al. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. Lancet Oncol. 2015;16(7):787–794. doi:10.1016/S1470-2045(15)00011-X26028518
   PubMed Web of Science ®Google Scholar
• Rosenthal SA, Hu C, Sartor O, et al. Effect of chemotherapy with docetaxel with androgen suppression and radiotherapy for localized high-risk prostate cancer: the randomized phase III NRG oncology RTOG 0521 trial. J Clin Oncol. 2019;37(14):1159–1168. doi:10.1200/JCO.18.0215830860948
   PubMed Web of Science ®Google Scholar
• Roach M, Moughan J, Lawton CAF, et al. Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial. Lancet Oncol. 2018;19(11):1504–1515. doi:10.1016/S1470-2045(18)30528-X30316827
   PubMed Web of Science ®Google Scholar
• Spratt DE, Vargas HA, Zumsteg ZS, et al. Patterns of lymph node failure after dose-escalated radiotherapy: implications for extended pelvic lymph node coverage. Eur Urol. 2017;71(1):37–43. doi:10.1016/j.eururo.2016.07.04327523595
   PubMed Web of Science ®Google Scholar
• Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. 2009;181(3):956–962. doi:10.1016/j.juro.2008.11.03219167731
   PubMed Web of Science ®Google Scholar
• Wiegel T, Bartkowiak D, Bottke D, et al. Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial. Eur Urol. 2014;66(2):243–250. doi:10.1016/j.eururo.2014.03.01124680359
   PubMed Web of Science ®Google Scholar
• Bolla M, van Poppel H, Tombal B, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet London Engl. 2012;380(9858):2018‐2027. doi:10.1016/S0140-6736(12)61253-7
   Google Scholar
• Lawton CA, Winter K, Grignon D, Pilepich MV. Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31. J Clin Oncol. 2005;23(4):800–807. doi:10.1200/JCO.2005.08.14115681524
   PubMed Web of Science ®Google Scholar
• Tendulkar RD, Agrawal S, Gao T, et al. Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy. J Clin Oncol. 2016;34(30):3648–3654. doi:10.1200/JCO.2016.67.964727528718
   PubMed Web of Science ®Google Scholar
• Shipley WU, Seiferheld W, Lukka HR, et al. Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Engl J Med. 2017;376(5):417–428. doi:10.1056/NEJMoa160752928146658
   PubMed Web of Science ®Google Scholar
• Carrie C, Hasbini A, de Laroche G, et al. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol. 2016;17(6):747–756. doi:10.1016/S1470-2045(16)00111-X27160475
   PubMed Web of Science ®Google Scholar
• Pollack A, Karrison TG, Balogh AG, et al. Short term androgen deprivation therapy without or with pelvic lymph node treatment added to prostate bed only salvage radiotherapy: the NRG oncology/RTOG 0534 SPPORT trial. Int J Radiat Oncol. 2018;102(5):1605. doi:10.1016/j.ijrobp.2018.08.052
   Web of Science ®Google Scholar
• Wallis CJD, Saskin R, Choo R, et al. Surgery versus radiotherapy for clinically-localized prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016;70(1):21–30. doi:10.1016/j.eururo.2015.11.01026700655
   PubMed Web of Science ®Google Scholar
• Roach M, Ceron Lizarraga TL, Lazar AA. Radical prostatectomy versus radiation and androgen deprivation therapy for clinically localized prostate cancer: how good is the evidence? Int J Radiat Oncol. 2015;93(5):1064–1070. doi:10.1016/j.ijrobp.2015.08.005
   Web of Science ®Google Scholar
• Greenberger BA, Zaorsky NG, Den RB. Comparison of radical prostatectomy versus radiation and androgen deprivation therapy strategies as primary treatment for high-risk localized prostate cancer: a systematic review and meta-analysis. Eur Urol Focus. 2019. doi:10.1016/j.euf.2019.11.007
   Google Scholar
• Greenberger BA, Chen VE, Den RB. Combined modality therapies for high-risk prostate cancer: narrative review of current understanding and new directions. Front Oncol. 2019;9. doi:10.3389/fonc.2019.01273
   Web of Science ®Google Scholar
• Kishan AU, Cook RR, Ciezki JP, et al. Radical prostatectomy, external beam radiotherapy, or external beam radiotherapy with brachytherapy boost and disease progression and mortality in patients with Gleason score 9–10 prostate cancer. JAMA. 2018;319(9):896–905. doi:10.1001/jama.2018.058729509865
   PubMed Web of Science ®Google Scholar
• Tilki D, Chen M-H, Wu J, et al. Surgery vs radiotherapy in the management of biopsy Gleason score 9–10 prostate cancer and the risk of mortality. JAMA Oncol. 2018. doi:10.1001/jamaoncol.2018.4836
   Web of Science ®Google Scholar
• Muralidhar V, Mahal BA, Butler S, et al. Combined external beam radiation therapy and brachytherapy versus radical prostatectomy with adjuvant radiation therapy for Gleason 9–10 prostate cancer. J Urol. 2019;202(5):973–978. doi:10.1097/JU.000000000000035231144590
   PubMed Web of Science ®Google Scholar
• Lepor H. A review of surgical techniques for radical prostatectomy. Rev Urol. 2005;7(2):S11–S17.
   Google Scholar
• Koch MO, Smith JA. Blood loss during radical retropubic prostatectomy: is preoperative autologous blood donation indicated? J Urol. 1996;156(3):1077–1080. doi:10.1016/S0022-5347(01)65706-98709311
   PubMed Web of Science ®Google Scholar
• Lance RS, Freidrichs PA, Kane C, et al. A comparison of radical retropubic with perineal prostatectomy for localized prostate cancer within the Uniformed Services Urology Research Group: comparison of RRP with RPP for prostate cancer. BJU Int. 2001;87(1):61–65. doi:10.1046/j.1464-410x.2001.00023.x11121994
   PubMed Web of Science ®Google Scholar
• Chandrasekar T, Tilki D. Robotic-assisted vs. open radical prostatectomy: an update to the never-ending debate. Transl Androl Urol. 2018;7(S1):S120–S123. doi:10.21037/tau.2017.12.2029644178
   PubMed Web of Science ®Google Scholar
• Dinneen E, Haider A, Allen C, et al. NeuroSAFE robot-assisted laparoscopic prostatectomy versus standard robot-assisted laparoscopic prostatectomy for men with localised prostate cancer (NeuroSAFE PROOF): protocol for a randomised controlled feasibility study. BMJ Open. 2019;9(6):e028132. doi:10.1136/bmjopen-2018-028132
   Web of Science ®Google Scholar
• Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M. D. anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol. 2008;70(1):67–74. doi:10.1016/j.ijrobp.2007.06.054
   PubMed Web of Science ®Google Scholar
• Zietman AL, Bae K, Slater JD, et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. J Clin Oncol. 2010;28(7):1106–1111. doi:10.1200/JCO.2009.25.847520124169
   PubMed Web of Science ®Google Scholar
• Al-Mamgani A, van Putten WLJ, Heemsbergen WD, et al. Update of dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol. 2008;72(4):980–988. doi:10.1016/j.ijrobp.2008.02.073
   PubMed Web of Science ®Google Scholar
• Michalski JM, Moughan J, Purdy J, et al. Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: the NRG oncology RTOG 0126 randomized clinical trial. JAMA Oncol. 2018;4(6):e180039. doi:10.1001/jamaoncol.2018.003929543933
   PubMed Web of Science ®Google Scholar
• Roy S, Morgan SC. Hypofractionated radiotherapy for localized prostate cancer: when and for whom? Curr Urol Rep. 2019;20(9). doi:10.1007/s11934-019-0918-0
   Web of Science ®Google Scholar
• Fischer-Valuck BW, Rao YJ, Michalski JM. Intensity-modulated radiotherapy for prostate cancer. Transl Androl Urol. 2018;7(3):297–307. doi:10.21037/tau.2017.12.1630050791
   PubMed Web of Science ®Google Scholar
• Gay HA, Barthold HJ, O’Meara E, et al. Pelvic normal tissue contouring guidelines for radiation therapy: a Radiation Therapy Oncology Group consensus panel atlas. Int J Radiat Oncol. 2012;83(3):e353–e362. doi:10.1016/j.ijrobp.2012.01.023
   PubMed Web of Science ®Google Scholar
• Michalski JM, Lawton C, El Naqa I, et al. Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer. Int J Radiat Oncol. 2010;76(2):361–368. doi:10.1016/j.ijrobp.2009.02.006
   PubMed Web of Science ®Google Scholar
• Afkhami Ardekani M, Ghaffari H. Optimization of prostate brachytherapy techniques with polyethylene glycol–based hydrogel spacers: a systematic review. Brachytherapy. 2020;19(1):13–23. doi:10.1016/j.brachy.2019.08.00931542390
   PubMed Web of Science ®Google Scholar
• Giesler RB, Miles BJ, Cowen ME, Kattan MW. Assessing quality of life in men with clinically localized prostate cancer: development of a new instrument for use in multiple settings. Qual Life Res. 2000;9(6):645–665.11236855
   PubMed Web of Science ®Google Scholar
• Sosnowski R. Basic issues concerning health-related quality of life. Cent Eur J Urol. 2017;70(2):206–211. doi:10.5173/ceju.2017.923
   PubMed Web of Science ®Google Scholar
• Gandaglia G, Bray F, Cooperberg MR, et al. Prostate cancer registries: current status and future directions. Eur Urol. 2016;69(6):998–1012. doi:10.1016/j.eururo.2015.05.04626056070
   PubMed Web of Science ®Google Scholar
• Soni PD, Hartman HE, Dess RT, et al. Comparison of population-based observational studies with randomized trials in oncology. J Clin Oncol. 2019;37(14):1209–1216. doi:10.1200/JCO.18.0107430897037
   PubMed Web of Science ®Google Scholar
• Resnick MJ, Koyama T, Fan K-H, et al. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med. 2013;368(5):436–445. doi:10.1056/NEJMoa120997823363497
   PubMed Web of Science ®Google Scholar
• Barocas DA, Alvarez J, Resnick MJ, et al. Association between radiation therapy, surgery, or observation for localized prostate cancer and patient-reported outcomes after 3 years. JAMA. 2017;317(11):1126–1140. doi:10.1001/jama.2017.170428324093
   PubMed Web of Science ®Google Scholar
• Chen RC, Basak R, Meyer A-M, et al. Association between choice of radical prostatectomy, external beam radiotherapy, brachytherapy, or active surveillance and patient-reported quality of life among men with localized prostate cancer. JAMA. 2017;317(11):1141–1150. doi:10.1001/jama.2017.165228324092
   PubMed Web of Science ®Google Scholar
• Whiting PF, Moore THM, Jameson CM, et al. Symptomatic and quality-of-life outcomes after treatment for clinically localised prostate cancer: a systematic review. BJU Int. 2016;118(2):193–204. doi:10.1111/bju.1349927087414
   PubMed Web of Science ®Google Scholar
• Donovan JL, Hamdy FC, Lane JA, et al. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2016;375(15):1425–1437. doi:10.1056/NEJMoa160622127626365
   PubMed Web of Science ®Google Scholar
• Stranne J, Brasso K, Brennhovd B, et al. SPCG-15: a prospective randomized study comparing primary radical prostatectomy and primary radiotherapy plus androgen deprivation therapy for locally advanced prostate cancer. Scand J Urol. 2018;52(5–6):313–320. doi:10.1080/21681805.2018.152029530585526
   PubMed Web of Science ®Google Scholar
• Wolff D, Stieler F, Welzel G, et al. Volumetric modulated arc therapy (VMAT) vs. serial tomotherapy, step-and-shoot IMRT and 3D-conformal RT for treatment of prostate cancer. Radiother Oncol. 2009;93(2):226–233. doi:10.1016/j.radonc.2009.08.01119765846
   PubMed Web of Science ®Google Scholar
• Lennernäs B, Majumder K, Damber J-E, et al. Radical prostatectomy versus high-dose irradiation in localized/locally advanced prostate cancer: a Swedish multicenter randomized trial with patient-reported outcomes. Acta Oncol. 2015;54(6):875–881. doi:10.3109/0284186X.2014.97482725362844
   PubMed Web of Science ®Google Scholar
• Crook JM, Gomez-Iturriaga A, Wallace K, et al. Comparison of health-related quality of life 5 years after SPIRIT: surgical prostatectomy versus interstitial radiation intervention trial. J Clin Oncol. 2010. doi:10.1200/JCO.2010.31.7305
   Web of Science ®Google Scholar
• Giberti C, Chiono L, Gallo F, Schenone M, Gastaldi E. Radical retropubic prostatectomy versus brachytherapy for low-risk prostatic cancer: a prospective study. World J Urol. 2009;27(5):607–612. doi:10.1007/s00345-009-0418-919455340
   PubMed Web of Science ®Google Scholar
• Rodda S, Tyldesley S, Morris WJ, et al. ASCENDE-RT: an analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol. 2017;98(2):286–295. doi:10.1016/j.ijrobp.2017.01.008
   PubMed Web of Science ®Google Scholar
• Hoffman KE, Penson DF, Zhao Z, et al. Patient-reported outcomes through 5 years for active surveillance, surgery, brachytherapy, or external beam radiation with or without androgen deprivation therapy for localized prostate cancer. JAMA. 2020;323(2):149. doi:10.1001/jama.2019.2067531935027
   PubMed Web of Science ®Google Scholar
• Dacal K, Sereika SM, Greenspan SL. Quality of life in prostate cancer patients taking androgen deprivation therapy: quality of life in men with prostate cancer. J Am Geriatr Soc. 2006;54(1):85–90. doi:10.1111/j.1532-5415.2005.00567.x16420202
   PubMed Web of Science ®Google Scholar
• Cheung AS, de Rooy C, Hoermann R, Lim Joon D, Zajac JD, Grossmann M. Quality of life decrements in men with prostate cancer undergoing androgen deprivation therapy. Clin Endocrinol (Oxf). 2017;86(3):388–394. doi:10.1111/cen.1324927696495
   PubMed Web of Science ®Google Scholar
• Gay HA, Sanda MG, Liu J, et al. External beam radiation therapy or brachytherapy with or without short-course neoadjuvant androgen deprivation therapy: results of a multicenter, prospective study of quality of life. Int J Radiat Oncol. 2017;98(2):304–317. doi:10.1016/j.ijrobp.2017.02.019
   Web of Science ®Google Scholar
• Jenkins DK, Swanson GP, Jhavar SG, Wagner KR, Ha CS, Chen W. Worsening of Urinary Quality of Life (QOL) is seen in patients receiving delayed post-prostatectomy radiation. Int J Radiat Oncol. 2018;102(3):e121. doi:10.1016/j.ijrobp.2018.07.325
   Web of Science ®Google Scholar
• Melotek JM, Liao C, Liauw SL, Gao X. Quality of life after post-prostatectomy intensity modulated radiation therapy: pelvic nodal irradiation is not associated with worse bladder, bowel, or sexual outcomes. Gao X, ed. PLoS One. 2015;10(10):e0141639. doi:10.1371/journal.pone.014163926512986
   PubMed Web of Science ®Google Scholar
• van Stam M-A, Aaronson NK, Pos FJ, et al. The effect of salvage radiotherapy and its timing on the health-related quality of life of prostate cancer patients. Eur Urol. 2016;70(5):751–757. doi:10.1016/j.eururo.2016.03.01027016464
   PubMed Web of Science ®Google Scholar
• Eastham James A, Kattan Michael W, Eamonn R, et al. Risk factors for urinary incontinence after radical prostatectomy. J Urol. 1996;156(5):1707–1713. doi:10.1016/S0022-5347(01)65488-08863576
   PubMed Web of Science ®Google Scholar
• Gousse Angelo E, Shahar M, Marie-May L, Fishman Irving J. Artificial urinary sphincter for post-radical prostatectomy urinary incontinence: long-term subjective results. J Urol. 2001;166(5):1755–1758. doi:10.1016/S0022-5347(05)65668-611586217
   PubMed Web of Science ®Google Scholar
• Rehder P, Gozzi C. Transobturator sling suspension for male urinary incontinence including post-radical prostatectomy. Eur Urol. 2007;52(3):860–867. doi:10.1016/j.eururo.2007.01.11017316969
   PubMed Web of Science ®Google Scholar
• Burgio Kathryn L, Stutzman Ray E, Engel Bernard T. Behavioral training for post-prostatectomy urinary incontinence. J Urol. 1989;141(2):303–306. doi:10.1016/S0022-5347(17)40747-62913349
   PubMed Web of Science ®Google Scholar
• Smit SG, Heyns CF. Management of radiation cystitis. Nat Rev Urol. 2010;7(4):206–214. doi:10.1038/nrurol.2010.2320212517
   PubMed Web of Science ®Google Scholar
• Lee S-I, Park Y-A, Sohn S-K. Formalin application for the treatment of radiation-induced hemorrhagic proctitis. Yonsei Med J. 2007;48(1):97–100. doi:10.3349/ymj.2007.48.1.9717326251
   PubMed Web of Science ®Google Scholar
• Seow-Choen F, Goh H-S, Eu K-W, Ho Y-H, Tay S-K. A simple and effective treatment for hemorrhagic radiation proctitis using formalin. Dis Colon Rectum. 1993;36(2):135–138. doi:10.1007/BF020511688425416
   PubMed Web of Science ®Google Scholar
• Tam W, Moore J, Schoeman M. Treatment of radiation proctitis with argon plasma coagulation. Endoscopy. 2000;32(9):667–672. doi:10.1055/s-2000-902010989988
   PubMed Web of Science ®Google Scholar
• Zhou C, Adler DC, Becker L, et al. Effective treatment of chronic radiation proctitis using radiofrequency ablation. Therap Adv Gastroenterol. 2009;2(3):149–156. doi:10.1177/1756283X08103341
   PubMedGoogle Scholar
• Pinto A, Fidalgo P, Cravo M, et al. Short chain fatty acids are effective in short-term treatment of chronic radiation proctitis. Dis Colon Rectum. 1999;42(6):788–795. doi:10.1007/BF0223693710378604
   PubMed Web of Science ®Google Scholar
• Corman JM, McCLURE D, Pritchett R, Kozlowski P, Hampson NB. Treatment of radiation induced hemorrhagic cystitis with hyperbaric oxygen. J Urol. 2003;169(6):2200–2202. doi:10.1097/01.ju.0000063640.41307.c912771749
   PubMed Web of Science ®Google Scholar
• Woo TCS, Joseph D, Oxer H. Hyperbaric oxygen treatment for radiation proctitis. Int J Radiat Oncol. 1997;38(3):619–622. doi:10.1016/S0360-3016(97)00017-5
   Web of Science ®Google Scholar
• Incrocci L, Slob AK, Levendag PC. Sexual (dys)function after radiotherapy for prostate cancer: a review. Int J Radiat Oncol. 2002;52(3):681–693. doi:10.1016/S0360-3016(01)02727-4
   Web of Science ®Google Scholar
• Chung E, Brock G. Sexual rehabilitation and cancer survivorship: a state of art review of current literature and management strategies in male sexual dysfunction among prostate cancer survivors. J Sex Med. 2013;10(S1):102–111. doi:10.1111/j.1743-6109.2012.03005.x23387915
   PubMed Web of Science ®Google Scholar
• Zelefsky Michael J, Daniel S, Dunn BR, et al. Prophylactic sildenafil citrate improves select aspects of sexual function in men treated with radiotherapy for prostate cancer. J Urol. 2014;192(3):868–874. doi:10.1016/j.juro.2014.02.09724603102
   PubMed Web of Science ®Google Scholar
• Mazzola C, Mulhall JP. Penile rehabilitation after prostate cancer treatment: outcomes and practical algorithm. Urol Clin North Am. 2011;38(2):105–118. doi:10.1016/j.ucl.2011.03.00221621077
   PubMed Web of Science ®Google Scholar
• Dubocq FM, Bianco FJ, Maralani SJ, Forman JD, Dhabuwala CB. Outcome analysis of penile implant surgery after external beam radiation for prostate cancer. J Urol. 1997;158(5):1787–1790. doi:10.1016/S0022-5347(01)64129-69334602
   PubMed Web of Science ®Google Scholar
• Pahlajani G, Raina R, Jones S, Ali M, Zippe C. Vacuum erection devices revisited: its emerging role in the treatment of erectile dysfunction and early penile rehabilitation following prostate cancer therapy. J Sex Med. 2012;9(4):1182–1189. doi:10.1111/j.1743-6109.2010.01881.x21054791
   PubMed Web of Science ®Google Scholar
• Cormie P, Newton RU, Taaffe DR, Spry N, Galvão DA. Exercise therapy for sexual dysfunction after prostate cancer. Nat Rev Urol London. 2013;10(12):731–736. doi:10.1038/nrurol.2013.20624100515
   PubMed Web of Science ®Google Scholar
• Badr H, Taylor CLC. Sexual dysfunction and spousal communication in couples coping with prostate cancer. Psychooncology. 2009;18(7):735–746. doi:10.1002/pon.144919061199
   PubMed Web of Science ®Google Scholar
• Delobel J-B, Gnep K, Ospina JD, et al. Nomogram to predict rectal toxicity following prostate cancer radiotherapy. Sung S-Y, ed. PLoS One. 2017;12(6):e0179845. doi:10.1371/journal.pone.017984528640871
   PubMed Web of Science ®Google Scholar
• Valdagni R, Rancati T, Fiorino C, et al. Development of a set of nomograms to predict acute lower gastrointestinal toxicity for prostate cancer 3D-CRT. Int J Radiat Oncol. 2008;71(4):1065–1073. doi:10.1016/j.ijrobp.2007.11.037
   Web of Science ®Google Scholar
• Valdagni R, Kattan MW, Rancati T, et al. Is it time to tailor the prediction of radio-induced toxicity in prostate cancer patients? Building the first set of nomograms for late rectal syndrome. Int J Radiat Oncol. 2012;82(5):1957–1966. doi:10.1016/j.ijrobp.2011.03.028
   Web of Science ®Google Scholar
• Mathieu R, Arango JDO, Beckendorf V, et al. Nomograms to predict late urinary toxicity after prostate cancer radiotherapy. World J Urol. 2014;32(3):743–751. doi:10.1007/s00345-013-1146-823990073
   PubMed Web of Science ®Google Scholar
• Montie JE. Counseling the patient with localized prostate cancer. Urology. 1994;43:36–40. doi:10.1016/0090-4295(94)90216-X
   Web of Science ®Google Scholar
• Valicenti RK, Gomella LG, El-Gabry EA, et al. The multidisciplinary clinic approach to prostate cancer counseling and treatment. Semin Urol Oncol. 2000;18(3):188–191.10975490
   PubMedGoogle Scholar
• Gomella LG, Lin J, Hoffman-Censits J, et al. Enhancing prostate cancer care through the multidisciplinary clinic approach: a 15-year experience. J Oncol Pract. 2010;6(6):e5–e10. doi:10.1200/JOP.2010.00007121358951
   PubMedGoogle Scholar